Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “JAZZ PHARMACEUTICALS RESEARCH UK LIMITED”

15 pharma patents match "JAZZ PHARMACEUTICALS RESEARCH UK LIMITED" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 15
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 15 pharmaceutical patents matching "JAZZ PHARMACEUTICALS RESEARCH UK LIMITED" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

15 results for “JAZZ PHARMACEUTICALS RESEARCH UK LIMITED” · 30,257 patents in full index Clear search

  1. US 12427160

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  2. US 12403136

    Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  3. US 12396963

    Cannabidiol-type cannabinoid compound

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  4. US 12383512

    Cannabidiol-type cannabinoid compound

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  5. US 12383567

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  6. US 12364670

    Cannabidiol-type cannabinoid compound

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  7. US 12357586

    Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  8. US 12350253

    Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  9. US 12318356

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  10. US 12263139

    Use of cannabidiol in the treatment of tuberous sclerosis complex

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  11. US 12213985

    Oral cannabinoid formulations

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  12. US 12161607

    Combination of cannabinoids in the treatment of leukemia

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  13. US 12102619

    Methods of treating tuberous sclerosis complex with cannabidiol and everolimus

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  14. US 12064398

    Parenteral formulations

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  15. US 12064399

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted